These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 28597670)
1. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics]. Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275 [TBL] [Abstract][Full Text] [Related]
3. Detection of Anaplastic Lymphoma Kinase Gene Re-Arrangement in Non-Small Cell Lung Carcinoma in the Indian Population: Comparison of Techniques and Immunohistochemistry Clones. Shukla S; Pandey RK; Kant S; Garg R; Anand N; Kushwaha R; Malhotra KP; Srivastava A; Bhatt M; Husain N Turk Patoloji Derg; 2019; 35(1):36-45. PubMed ID: 30596395 [TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200 [TBL] [Abstract][Full Text] [Related]
5. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803 [TBL] [Abstract][Full Text] [Related]
6. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. Demidova I; Grinevich V; Avdalian A; Imyanitov E; Gikalo M; Savelov N; Novikova I; Samuilenkova O; Tiurin V; Ulianova E; Tsimafeyeu I; Tjulandin S Lung Cancer; 2017 Jan; 103():17-23. PubMed ID: 28024691 [TBL] [Abstract][Full Text] [Related]
7. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247 [TBL] [Abstract][Full Text] [Related]
8. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC). Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459 [TBL] [Abstract][Full Text] [Related]
10. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study. Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850 [TBL] [Abstract][Full Text] [Related]
11. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization. Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400 [TBL] [Abstract][Full Text] [Related]
13. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance. Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018 [TBL] [Abstract][Full Text] [Related]
15. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695 [TBL] [Abstract][Full Text] [Related]
17. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111 [TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of immunohistochemistry and fluorescent Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679 [TBL] [Abstract][Full Text] [Related]
19. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm. Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631 [TBL] [Abstract][Full Text] [Related]
20. Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study. Li L; Li W; Wu C; Xi Y; Guo L; Ji Y; Jiang L; Li J; Yun J; Chen G; Li Y; Liu Y; Mu D; Han Y; Sun L; Xia Q; Teng X; Che N; Wu W; Qiu X; Liu C; Yan X; Li D; Zhang Z; Wang Z; Li Y; Wang Z; Guo L; Nie X; Geng J; Zhou J; Ying J Cancer Commun (Lond); 2024 Sep; 44(9):992-1004. PubMed ID: 39016057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]